|Harvard Business School, MBA|
Bill Helman joined Greylock in 1984 and led Greylock’s investments in Zipcar (ZIP), Aveo Pharmaceuticals (Nasdaq: AVEO), Exact Sciences, Upromise (merged with Sallie Mae), Outlooksoft (merged with SAP), Tessera (merged with IXL), Ontogeny (merged with Curis), Hyperion Software (merged with Oracle), Filene’s Basement, Pharmacopeia, Millennium Pharmaceuticals (merged with Takeda), Vertex Pharmaceuticals, Mitotix (merged with GPC Biotech) and Reveal Imaging (merged with SAIC). In addition, Bill serves on the Board of Directors of Ford Motor Company, on the Board of Trustees of Dartmouth College where he serves as Chair of the Investment Committee and on the Board of Harvard Management Company. He is on the Board of the Isabella Stewart Gardner Museum, the Broad Institute, the Damon Runyon Cancer Research Foundation, the Dartmouth Hitchcock Medical Center, and The Steppingstone Foundation and is a member of the Harvard Medical School Board of Fellows. He is a graduate of Dartmouth College (A.B.) and the Harvard Business School (M.B.A.).